Welcome to our dedicated page for Microbot Medical news (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Medical stock.
Microbot Medical, Inc. (NASDAQ: MBOT) is a pioneering pre-clinical medical device company focused on developing groundbreaking micro-robotic medical technologies. Established with the vision to transform minimally invasive surgeries—a fast-growing sector estimated to be close to $20 billion by 2015—Microbot Medical aims to provide cutting-edge micro-invasive technologies that assist physicians in targeting disease sites with unmatched precision. The company's innovative platforms, such as LIBERTY and the Self-Cleaning Shunt (SCS), are designed to improve surgical outcomes and the quality of life for millions of patients globally.
One of Microbot Medical's core technologies, the Virob platform, is an autonomous advancing micro-robot (AAMR) less than 1mm in diameter. This micro-robot can advance forward and backward autonomously, providing precise navigation through the body. Similarly, the LIBERTY Endovascular Robotic Surgical System aims to revolutionize endovascular procedures by eliminating the need for bulky and expensive equipment while reducing radiation exposure and physician strain.
Microbot Medical has been achieving significant milestones, including positive results from its pivotal GLP pre-clinical study and its recent Investigational Device Exemption (IDE) application to the FDA. These advancements pave the way for the company's first human clinical trials. Furthermore, the company has secured both domestic and global patents, fortifying its product portfolio and creating significant barriers to entry for competitors.
Microbot Medical is actively engaging in pre-commercial activities and strategic partnerships to ensure efficient commercialization channels for the LIBERTY system once it receives regulatory approval. The company is committed to advancing its technologies and aims to integrate future capabilities such as remote operations, imaging integration, and AI functionalities.
Despite challenges such as the COVID-19 pandemic and recent geopolitical events in Israel, Microbot Medical continues to meet its planned timelines and milestones. The company’s operations in Israel, the USA, and other parts of the globe remain uninterrupted, and it believes it will achieve regulatory and commercial milestones as scheduled.
For further information about Microbot Medical, please visit www.microbotmedical.com.
Microbot Medical (Nasdaq: MBOT) announced the successful enrollment of the first patient in its pivotal human clinical trial for the LIBERTY® Endovascular Robotic Surgical System. The procedure was conducted at Brigham and Women’s Hospital (BWH) in Boston, led by Dr. Dmitry Rabkin. This trial, part of an Investigational Device Exemption (IDE), aims to gather data to support the future FDA submission and commercialization of LIBERTY®. Juan Diaz-Cartelle, MD, Chief Medical Officer, highlighted this milestone as important for bringing LIBERTY® to U.S. physicians and expressed optimism for further patient enrollments.
Microbot Medical has announced a partnership with Baptist Hospital of Miami to participate in its pivotal human clinical trial for the LIBERTY Endovascular Robotic Surgical System. This follows recent FDA approval to start the trial. Baptist Hospital is the second site to enroll, joining Brigham and Women's Hospital. The trial has received Institutional Review Board approval, and a Clinical Trial Agreement has been signed. Dr. Ripal Gandhi will be the principal investigator. The LIBERTY technology aims to revolutionize endovascular procedures, with significant interest from leading healthcare institutions.
Microbot Medical has partnered with Brigham and Women's Hospital (BWH) to conduct a pivotal human clinical trial for its LIBERTY® Endovascular Robotic Surgical System. This follows the FDA's approval to commence the trial. BWH has received multiple LIBERTY systems and completed the Site Initiation Visit, which included training for clinical staff. Dr. Dmitry Rabkin will lead the study at BWH. Microbot is also engaging other leading centers to participate in the trial.
Microbot Medical has announced that Brigham and Women’s Hospital (BWH) in Boston will be a site for its pivotal human clinical trial for the LIBERTY Endovascular Robotic Surgical System as part of its Investigational Device Exemption (IDE) application. Dr. Dmitry Rabkin has been appointed as the principal investigator at BWH. The site initiation visit has been completed, and BWH staff have been trained on the clinical study protocols. Additionally, a shipment of LIBERTY investigational units has been delivered to BWH. Microbot Medical is also in the process of enlisting other leading centers for the clinical trial.
Microbot Medical (NASDAQ: MBOT) announced the closing of a $2.35 million registered direct offering priced at-the-market under Nasdaq rules, selling 1,566,669 shares at $1.50 per share. Concurrently, the company issued unregistered Series F preferred investment options for up to 3,133,338 shares at $1.50 per share, exercisable for two years. H.C. Wainwright & Co. acted as the exclusive placement agent. The company plans to use the net proceeds for the development and commercialization of the LIBERTY® Robotic System, expansion of its IP portfolio, and general corporate purposes.
Microbot Medical (Nasdaq: MBOT) has announced a registered direct offering for the purchase and sale of 1,566,669 shares at $1.50 per share, totaling approximately $2.35 million in gross proceeds. Concurrently, unregistered series F preferred investment options to purchase up to 3,133,338 shares at the same price will be issued in a private placement. The closing is expected around June 4, 2024, pending customary conditions. H.C. Wainwright & Co. is the exclusive placement agent. The net proceeds will fund the development and commercialization of the LIBERTY® Robotic System, other IP projects, and general corporate purposes.
Microbot Medical has received FDA approval to start its pivotal human clinical trial for the LIBERTY® Endovascular Robotic Surgical System.
The trial will be conducted in the U.S. and will complement preclinical data to support a future 510(k) submission. The company has signed a clinical trial service agreement with a leading academic medical center and is engaging additional centers.
In parallel, Microbot Medical is completing biocompatibility tests required for the IDE application. CEO Harel Gadot expressed confidence in the technology and commitment to achieving regulatory clearance and commercialization.
Microbot Medical Inc. (Nasdaq: MBOT) has announced the successful completion of the first phase of its collaboration with Corewell Health, showcasing the technical capabilities of its LIBERTY® Endovascular Robotic Surgical System. The partnership aims to explore remote endovascular procedures utilizing the LIBERTY System. Led by Dr. Ryan Madder, the collaboration has shown promising results in a pre-clinical study published in the Journal of the American College of Cardiology: Cardiovascular Interventions.
FAQ
What is the current stock price of Microbot Medical (MBOT)?
What is the market cap of Microbot Medical (MBOT)?
What is Microbot Medical, Inc.?
What is the LIBERTY Endovascular Robotic Surgical System?
What recent achievements has Microbot Medical accomplished?
What are the core technologies developed by Microbot Medical?
What is the vision of Microbot Medical?
How is Microbot Medical preparing for commercialization?
What impact do recent geopolitical events have on Microbot Medical's operations?
What is the Self-Cleaning Shunt (SCS) developed by Microbot Medical?
Who is acting as the exclusive placement agent for Microbot Medical's offering?
How can I get more information about Microbot Medical?
